Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (STIMULI)

Clinical Trial ID NCT02046733

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.	Lancet Oncol	2012	5.32
2	Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.	J Clin Oncol	2012	4.44
3	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.	Ann Oncol	2012	2.14
4	Immunotherapy in the treatment of non-small cell lung cancer.	Lung Cancer	2014	1.35
5	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
6	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
7	Advances in immunotherapy for treatment of lung cancer.	Cancer Biol Med	2015	0.95
8	Immunotherapy for lung cancer: advances and prospects.	Am J Clin Exp Immunol	2016	0.89
9	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.	Oncologist	2016	0.78
10	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?	ESMO Open	2016	0.77